Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

1. Garassino, M.C.
2. Cho, B.-C.
3. Kim, J.-H.
4. Mazières, J.
5. Vansteenkiste, J.
6. Lena, H.
7. Jaime, J.C.
8. Gray, J.E.
9. Powderly, J.
10. Chouaid, C.
11. Bidoli, P.
12. Wheatley-Price, P.
13. Park, K.
14. Soo, R.A.
15. Poole, L.
16. Wadsworth, C.
17. Dennis, P.A.
18. Rizvi, N.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.LUNGCAN.2020.06.032 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus